Oncogenes Meet Metabolism (häftad)
Format
Häftad (Paperback / softback)
Språk
Engelska
Antal sidor
265
Utgivningsdatum
2010-11-30
Upplaga
Softcover reprint of hardcover 1st ed. 2008
Förlag
Springer-Verlag Berlin and Heidelberg GmbH & Co. K
Medarbetare
Kroemer, Guido (ed.), Mumberg, Dominik (ed.), Petersen, Kirstin (ed.), Riefke, Björn (ed.), Steger-Hartmann, Thomas (ed.), Keun, Kector (ed.)
Illustrationer
XV, 265 p.
Dimensioner
210 x 130 x 19 mm
Vikt
419 g
Antal komponenter
1
Komponenter
1 Paperback / softback
ISBN
9783642098406

Oncogenes Meet Metabolism

From Deregulated Genes to a Broader Understanding of Tumour Physiology

Häftad,  Engelska, 2010-11-30
2311
  • Skickas från oss inom 5-8 vardagar.
  • Fri frakt över 249 kr för privatkunder i Sverige.
Finns även som
Visa alla 2 format & utgåvor
In 1920s, Otto Warburg described the phenomenon of aerobic glycolysis, the ability of tumour cells to convert glucose to lactate in the presence of normal oxygen conditions. Warburgs hypothesis of an altered metabolism in cancer cells found no immediate acceptance, though it was latter confirmed for most human tumours. With the advent of molecular biology the focus in tumour research has shifted towards the search for oncogenes. However, the interest in cancer molecular profiling eventually led to a renaissance of the Warburg effect trying to combine genetic alterations with effects on metabolism with the help of modern analytic technologies to rapidly analyze broad varieties of metabolites in various tissues and bodyfluids (metabonomics).
Visa hela texten

Passar bra ihop

  1. Oncogenes Meet Metabolism
  2. +
  3. Bad Therapy

De som köpt den här boken har ofta också köpt Bad Therapy av Abigail Shrier (inbunden).

Köp båda 2 för 2576 kr

Kundrecensioner

Har du läst boken? Sätt ditt betyg »

Innehållsförteckning

Mitochondria and Cancer.- Role of the Metabolic Stress Responses of Apoptosis and Autophagy in Tumor Suppression.- The Interplay Between MYC and HIF in the Warburg Effect.- Using Metabolomics to Monitor Anticancer Drugs.- Biomarker Discovery for Drug Development and Translational Medicine Using Metabonomics.- Pyruvate Kinase Type M2: A Key Regulator Within the Tumour Metabolome and a Tool for Metabolic Profiling of Tumours.- Molecular Imaging of Tumor Metabolism and Apoptosis.- Minimally Invasive Biomarkers for Therapy Monitoring.- Use of Metabolic Pathway Flux Information in Anticancer Drug Design.- Cancer Diagnostics Using 1H-NMR-Based Metabonomics.- Human Metabolic Phenotyping and Metabolome Wide Association Studies.- Defining Personal Nutrition and Metabolic Health Through Metabonomics.